Gerratana, Lorenzo
Davis, Andrew A.
Velimirovic, Marko
Clifton, Katherine
Hensing, Whitney L.
Shah, Ami N.
Dai, Charles S.
Reduzzi, Carolina
D’Amico, Paolo
Wehbe, Firas
Medford, Arielle
Wander, Seth A.
Gradishar, William J.
Behdad, Amir
Puglisi, Fabio
Ma, Cynthia X.
Bardia, Aditya
Cristofanilli, Massimo
Funding for this research was provided by:
Italian League for the Fight against Cancer (Healthcare research 2018—5 × mille program)
Italian Ministry of Health (Ricerca Corrente)
Ministero della Salute (RF-2016-02362544)
OncoSET Precision Medicine Program
Lynn Sage Cancer Research Foundation
Article History
Received: 17 January 2023
Accepted: 24 September 2023
First Online: 2 October 2023
Declarations
:
: Data were combined and shared under a data use agreement and approved by the institutional review boards (IRB) of the three sites (Washington University School of Medicine St. Louis, MO; IRB#202101147, Northwestern University, Chicago, IL; IRB#STU00214133 and Massachusetts General Hospital, Boston, MA; IRB#2013P000848). The requirement for informed consent was waived by the IRB for this de-identified analysis. The study was performed in concordance with the Health Insurance Portability and Accountability Act and the Declaration of Helsinki.
: Not applicable.
: L. Gerratana reports consulting or advisory role: AstraZeneca, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Incyte, Novartis, Pfizer, Menarini Stemmline, AbbVie; research funding: Menarini Silicon Biosystems. A. A. Davis reports participating in a scientific advisory board for Pfizer, Inc. F. Puglisi Reports consulting or advisory roles from Roche, MSD, AstraZeneca, Novartis, Lilly, Pfizer, Pierre Fabre, Daiichi Sankyo, Eisai, Amgen, in addition to research funding from Eisai, AstraZeneca, Roche. C.X. Ma holds consultant or advisory roles from Novartis, Seattle Genetics, Agendia, AstraZeneca, Athenex, Bayer HealthCare Pharmaceuticals, Biovica Inc, Eisai, Olaris Inc, Philips Electronics North America, Puma Biotechnology, and SanofiGenzyme, in addition to research funding from Pfizer and Puma Biotechnology. A. Bardia reports consulting or advisory roles with Novartis, Genentech, Pfizer, Spectrum Pharmaceuticals, bioTheranostics, Merck, Radius Health, Immunomedics, Novartis, Genentech/Roche, Radius Health, Innocrin Pharm, Sanofi, Puma Biotechnology, Daiichi Sankyo/Astra Zeneca, Foundation Medicine, Phillips Healthcare. He reports research funding from Genetech (Inst), Novartis (Inst), Pfizer (Inst), Merck (Inst), Sanofi (Inst), Radius Health (Inst), Immunomedics (Inst), Astra Zeneca/Daiichi Sankyo (Inst). M. Cristofanilli reports consulting fees from Novartis, Menarini, Eli Lilly, Sermonix, G1 Therapeutics, Foundation Medicine, Astra Zeneca, Pfizer Inc. Consulting/lecture fees from Foundation Medicine and Pfizer Inc. Travel support from Foundation Medicine. Participation on a Date Safety Monitoring Board or Advisory Board for Merck and Astra Zenca. Research funding from Pfizer Inc, Menarini, Eli Lilly, and G1 Therapuetics. The remaining authors report no conflicts of interest.